MDMA
Discover related
4 sources
How the databases line up — = agree, ≈ partial, ≠ differ. In lists, shared items appear in every source and unique ones in only one (matched case-insensitively).
| PsychonautWiki | TripSit | Pharmacology | PiHKAL | ||
|---|---|---|---|---|---|
| Classification | |||||
| Class / category | — | — | ≈ | ||
| Also known as | MDMAMollyMandyEmmaMDEcstasyEXXTCRollsBeansPingers | mollyecstasyadamxtcmandyxmd | — | MDMADAMECSTASY3,4-METHYLENEDIOXY-N-METHYLAMPHETAMINE | ≈ |
| Safety | |||||
| Addiction potential | moderately addictive with a high potential for abuse | — | — | — | |
| Toxicity | exact toxic dosage is unknown | — | — | — | |
| Dangerous interactions | — | — | ≈ | ||
| Unsafe interactions | — | — | ≈ | ||
| Dose · Oral | |||||
| Threshold | 20 mg | — | — | — | |
| Light | 20–80 mg | 40–75 mg | — | — | ≠ |
| Common | 80–120 mg | 75–125 mg | — | 80–150 mg | ≠ |
| Strong | 120–150 mg | 125–175 mg | — | — | ≠ |
| Heavy | 150 mg+ | 175 mg+ | — | — | ≠ |
| Dose · Insufflated | |||||
| Light | — | 30–70 mg | — | — | |
| Common | — | 70–120 mg | — | — | |
| Strong | — | 120–165 mg | — | — | |
| Heavy | — | 165 mg+ | — | — | |
| Dose · Rectal | |||||
| Light | — | 30–70 mg | — | — | |
| Common | — | 70–120 mg | — | — | |
| Strong | — | 120–165 mg | — | — | |
| Heavy | — | 165 mg+ | — | — | |
| Duration | |||||
| Onset | 30–45 minutes | 20–70 minutes | — | — | ≠ |
| Total | 3–6 hours | 3–5 hours | — | 4–6 hours | ≠ |
| After-effects | 12–48 hours | 1–72 hours | — | — | ≠ |
| Pharmacology | |||||
| Receptor activity | — | — | Sodium-dependent serotonin transporterSodium-dependent dopamine transporter5-hydroxytryptamine receptor 1ASerotonin 1B/1D receptor5-hydroxytryptamine receptor 2C5-hydroxytryptamine receptor 2ATransporter | — | |
| Half-life | — | — | 6–10 (though duration of effects is typically actually 3–5 hours) The present study compared the disposition and metabolism of the recreational drug (+/-) 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") in squirrel monkeys and humans because the squirrel monkey has been extensively studied for MDMA neurotoxicity. ... The elimination half-life of MDMA was considerably shorter in squirrel monkeys than in humans (2-3 versus 6-9 hours). ... ... In this study, we examine MDMA pharmacokinetics in rats given low (2 mg/kg) and high (10 mg/kg) doses of racemic MDMA via intraperitoneal, subcutaneous, and oral routes. Repeated blood specimens were collected from venous catheters, and plasma was assayed for MDMA and its metabolites, 4-hydroxy-3-methoxymethamphetamine (HMMA) and 3,4-methylenedioxyamphetamine (MDA), by gas chromatography-mass spectrometry. ... MDMA plasma half-lives were <1 hr for low-dose groups, whereas HMMA and MDA half-lives were >2 hr. ... ... Elimination half-life was 8.6 hr /(75 mg)/ and 7.7 hr /(125 mg)/ for low and high dose 3,4-methylenedioxymethamphetamine /in eight men with experience in the recreational use of 3,4-methylenedioxymethamphetamine/ ... ... /The/ half-life of (R)-3,4-methylenedioxymethamphetamine (5.8 +/- 2.2 hr) was significantly longer than that of the S-enantiomer (3.6 +/- 0.9 hr). ... Studies to characterize the pharmacokinetics of the enantiomers of MDMA were conducted in rats using the iliac arterial cannulation. Two routes of administration, intravenous and subcutaneous, were evaluated at two dose levels for each route [20 and 40 mg/kg (+/-)-MDMA for subcutaneous, 10 and 20 mg/kg (+/-)-MDMA for intravenous administrations]. The average half-life (+/- SD) for all dosing groups was 2.5 +/- 0.8 hr for (-)-(R)-MDMA and 2.2 +/- 0.8 hr for (+)-(S)-MDMA. ... | — | |
Dose at a glance
Each database's primary-route ladder on one shared scale — see where ranges line up or shift.
Duration at a glance
Total duration on one shared scale.
TripSit summary
The world's most popular empathogen with powerful pro-social effects. Has been strongly linked to cognitive decline in excess. Popular at parties, it is often sold in powder or in pills, and may be adulterated with other similar chemicals.
PiHKAL summary
The classic entactogen (Ecstasy), typically used therapeutically around 120 milligrams with an optional smaller top-up, and commonly followed by next-day tiredness. Its more potent isomer is the opposite of what holds for classic psychedelics, and it does not cross-tolerate with MDA, suggesting a distinct mechanism; heavy repeated dosing produces rapid, near-complete tolerance.
Fact-sheets from PsychonautWiki. Harm-reduction reference only — not medical advice.